National Association of Pharmacy Regulatory Authorities
National Association of Pharmacy Regulatory Authorities

Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Reset
Print Friendly Export to CSV
Drug Name Comment Schedule Date
Labetalol and its saltsF1 I SEP / 98
Lacosamide or its derivativesPDL I DEC / 13
Lactic acidPDL

when recommended for parenteral use as a tissue sclerosing agent

 I DEC / 13
Lactic acid.

in preparations in concentrations of more than 10% except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses

 III DEC / 14
Lactulose III SEP / 98
Lamivudine and its saltsF1 I SEP / 98
Lamotrigine and its saltsF1 I SEP / 98
LanadelumabPDL I NOV / 18
Lanreotide and its saltsF1 I MAY / 09
Lansoprazole and its saltsF1 I SEP / 98
Lanthanum salts.F1 when sold for the treatment of hyperphosphatemia I FEB / 08
Lapatinib and its saltsF1 I MAR / 11
LaronidaseF1 I APR / 07
Ledipasvir or its saltsPDL I DEC / 14
Lefetamine and any Salt thereofC4 I JAN / 03
Leflunomide and its saltsF1 I DEC / 01
LenalidomideF1 I MAY / 09
Lenvatinib or its saltsPDL I AUG / 16
Letermovir or its saltsPDL I DEC / 17
LetrozoleF1 I SEP / 98
Leucovorin and its saltsF1 I SEP / 98
Leuprolide and its saltsF1 I SEP / 98
Levallorphane and its salts I SEP / 98
Levamisole and its saltsF2 I SEP / 98
Levargorphane and its salts II SEP / 98
LevetiracetamF1 I JUN / 06
Levobunolol and its saltsF1 I SEP / 98
Levocabastine and its salts and derivativesF1 I SEP / 98
Levocarnitine and its salts and derivativesF1 when sold for the treatment of primary or secondary levocarnitine deficiency I DEC / 11
Levodopa and its saltsF1 I SEP / 98
LevomethorphanN I JUN / 02
Levomilnacipran or its saltsPDL I JUN / 15
LevomoramideN I JUN / 02
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
LevophenacylmorphanN I JUN / 02
LevorphanolN I JUN / 02
LidocainePDL

when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher

 I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

 III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

 U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its saltsPDL I MAR / 18
Linagliptin or its salts or derivativesPDL I DEC / 13
Lincomycin or its salts or derivativesPDL

Including but not limited to: Clindamycin 

 I DEC / 18
Lindane II SEP / 98
Linezolid and its saltsF1 I JUL / 03
Linezolid and its salts.F1 I JUN / 03
Liothyronine and its saltsF2 I SEP / 98
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its saltsPDL I DEC / 13
Lisinopril and its salts and derivativesF1 I SEP / 98
Lithium and its saltsF1 I SEP / 98
Lixisenatide or its saltsPDL I JUN / 17
Lodoxamide and its salts and derivativesF1 I SEP / 98
Lomefloxacin and its saltsF1 I SEP / 98
Lomitapide or its saltsPDL I FEB / 14
LomustineF1 I SEP / 98
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
LopinavirF1 I JUL / 03
LoprazolamTS I JUN / 02
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorazepam and its saltsTS I SEP / 98
Lorlatinib or its salts PDL I MAR / 19
LormetazepamTS I JUN / 02
Losartan and its saltsF1 I SEP / 98
Losoxantrone and its saltsF1 I SEP / 98
LotilanerPDL

For veterinary use

 I MAR / 18
LovastatinPDL

except in oral dosage form that provides 1 milligram (mg) or less per daily dose

 I DEC / 14
Loxapine and its saltsF1 I SEP / 98
Lumacaftor or its salts or derivativesPDL I AUG / 16
LumiracoxibF1 I MAY / 09
Lutropin alfaF1 I OCT / 07
Lyme Disease vaccine I FEB / 02

77 result(s)

Print Friendly Export to CSV

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled